Smell, taste and chemesthesis disorders in patients with the SARS-CoV-2 Omicron variant in China

INTRODUCTION

Coronavirus disease 2019 (COVID-19) was first detected in Wuhan in December 2019, and rapidly spread throughout more than 80 countries ^(1,2). Information from the World Health Organization shows that the number of confirmed COVID-19 cases was 756,411,740 by 16 February, 2023 (https://covid19.who.int). There are reports that chemosensory disorders are important symptoms of COVID-19 infection ^(3–5). Studies from the United States, Europe, Malaysia, and Singapore demonstrated that 12%– 88% of COVID-19-infected patients have olfactory and taste disorders ^(4,6–8), while studies from China reported that 5%–25% of patients have smell and/or taste disorder ^(9,10). The Omicron variant of SARS-CoV-2 was first detected in South Africa in November 2021, and became the main epidemic strain in the world by 15 January 2022 ^(11,12). Some studies have found that the Omicron variant causes less smell and taste dysfunction than non-Omicron SARS-CoV-2 ^(13–15). Further, a meta-analysis found that the prevalence rates of olfactory dysfunction caused by the Omicron variant are 8%–17% and 2%–17% the in UK and USA, respectively ⁽¹⁵⁾.

In China, the prevalence of olfactory dysfunction caused by the Omicron variant is reported as 0–9% ^(16–20); however, the sample sizes of studies to date have been relatively small and researchers have focused on patient characteristics and clinical symptoms, with insufficient discussion of chemosensory changes.

Chemosensory sensation (including smell, taste, and chemesthesis) have important roles in sensing potential threats, such as toxins, bacteria, and chemical irritants ⁽²¹⁾, but most relevant studies have focused solely on smell and taste, and ignored chemesthesis, which is defined as detection of burning, cooling, or tingling in the mouth ^(5,21). Since these three systems are independent sensory systems, with distinct peripheral and central neural mechanisms ⁽²²⁾, it is necessary to explore the influence of COVID-19 on these three senses separately. Further, chemosensory disturbances can result in qualitative changes or quantitative reductions in smell or taste, associated with different mechanisms. Qualitative changes include parosmia (things smell different from usual), phantosmia (hallucination of olfactory senses), smell fluctuation, parageusia (distorted taste sensations) and phantogeusia (hallucination of gustatory senses). Quantitative reductions include anosmia (complete loss of olfaction), hyposmia (partial loss of olfaction), ageusia (loss of all or specific gustatory senses) and hypogeusia (reduced ability to taste things) ^(23,24). Previous studies have generally explored changes or reductions of smell and taste, but have rarely classified patient conditions according to the qualitative of the disorders.

There is a pressing need to conduct a cross-sectional study to assess the effects of Omicron on patient smell, taste, and chemesthesis in China. The primary aim of this study was to investigate the prevalence of chemosensory disorders, as well as qualitative and quantitative changes of the chemosensory senses during Omicron infection. A secondary aim was to identify factors associated with chemosensory disorders, including sex, age, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or specific conditions, as well as COVID-19 related characteristics.

MATERIALS AND METHODS

RESULTS

Smell disorder

The data presented in Table 2 show that there was a statistically significant difference in smoking status between patients with and without smell disorder (p < 0.05); where smell disorder was significantly more common among patients who were current or former smokers (p < 0.05). No statistically significant differences in other demographic characteristics, including sex, age group, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or special condition, were found between patients with and without smell disorder (all p > 0.05). Significant differences in rehabilitation status, COVID-19-related symptoms (lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea and fatigue), and COVID-19 vaccination status, were also observed between patients with and without smell disorder (all p < 0.05). Chi-square analysis indicated that patients with symptoms including lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea, and fatigue, were prone to having smell disorder. Further, patients who did not undergo COVID-19 vaccination were more likely to experience smell disorder (p < 0.05). Associations between specific types of smell disorder (anosmia, hyposmia, parosmia, phantosmia, and olfactory fluctuation) and demographic/COVID-19-related characteristics are presented in the supplemental material (Table S1–S5).

View this table:

• View inline
• View popup

Table 2. Association between smell disorder and demographic/COVID-19-related characteristics among patients

Only 4.8% (60/1245) of patients reported parosmia, while 7.9% (98/1245) reported phantosmia. Pleasantness rating score on 100-point scale of the distorted smell caused by parosmia was 25.72 ± 24.81 (Mean ± SD), and that of phantom smells was 26.74 ± 25.98 (Mean ± SD). Parosmic individuals mostly reported smells of food (e.g., meat, rice, or soup) or other daily necessities (e.g., toothpaste, shampoo, or liquid detergent) that became roasted, burnt, or spoiled (e.g., “The smell of chicken soup turned to burning”). In phantosmic individuals, the most frequently reported phantom smells were smoky, burnt, and rotten.

Patients rated their smell function before and during COVID-19 on a 100-point scale. Compared to scores before COVID-19 (88.53 ± 13.24, Mean ± SD), those during COVID-19 (52.38 ± 32.83, Mean ± SD) were significantly lower (t = 38.386, p < 0.001) (Figure 1).

• Download figure
• Open in new tab

Figure 1.

The results of self-rating of smell, taste, and chemesthesis function

^***p < 0.001.

DISCUSSION

In the current study, we found that the prevalence rates of smell, taste, and chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Previous studies reported prevalence rates of olfactory dysfunction ranging from 3.2% to 98.3% and of taste dysfunction ranging from 5.6% to 62.7% ^(28,29). Previous research has found that the reported prevalence of smell, taste, and chemesthesis disorder varies according to differences in population, assessment method, and virus strain ⁽²⁸⁾. A meta-analysis based on data from 24 studies, including over 8400 participants from 13 countries, found the pooled prevalence rates of patients with smell and taste dysfunction were 41.0% and 38.2%, respectively ⁽²⁹⁾. Another meta-analysis involving 18 studies showed that the prevalence of alteration of the sense of smell or taste was 47% ⁽³⁰⁾. Importantly, recent studies have focused primarily on quantitative changes in smell and taste, while qualitative changes of smell and taste were not addressed ^(29,31–33); however, we included five types of smell disorder (anosmia, hyposmia, parosmia, phantosmia and olfactory fluctuation), and four types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) in our study. The prevalence of anosmia in our study was 23.3%, that of hyposmia was 42.5%, ageusia was 19.0%, and hypogeusia was 40.1%. Studies have also found that the prevalence of smell and taste disorder decreased during the period of Omicron variant dominance, but remained more than 30%, similar to our findings ^(28,34).

Males are reported to be more prone to loss of smell and taste senses than females ⁽³⁵⁾; however, our data demonstrate that females were more prone to complete loss of olfaction, similar to the findings of Lechien et al. ^(6,8). In terms of taste loss, we did not detect significant differences between the sexes, similar to Al-Rawi et al. ^(3,36). Further, Al-Rawi et al. found more significant smell and taste loss among individuals in their late 30s ⁽³⁾, consistent with our finding that patients aged 30–39 years are more prone to anosmia and ageusia. Previous research showed that smokers are more vulnerable to anosmia and ageusia ⁽³⁵⁾; however, we detected no significant differences between smokers and non-smokers in terms of anosmia and ageusia in our study. Interestingly, we found that smoking had adverse effects on smell disorders in general.

We also found that some COVID-19 related symptoms, such as lack of appetite, dyspnea, and fatigue, were associated with chemosensory disorder rates. Associations of these factors with chemosensory disorders have been reported in previous research ^(7,8); however, whether they are risk factors for chemosensory disorders requires further study.

In the current study, we report the prevalence, quality, and quantity of chemosensory changes in patients infected with the Omicron variant in China. Patients often confuse chemesthesis with smell and taste when self-reporting, thus our survey included an expanded section relating to chemesthesis, with the aim of better distinguishing the influences of COVID-19 infection on smell, taste and chemesthesis. We also made detailed distinctions among the quality and quantity of changes in smell and taste, and found that these changes differed in the COVID-19 infected population, which may provide reference data for the follow-up research on the mechanism underlying COVID-19 influence on smell and taste. Moreover, we expanded the Chinese version of the GCCR core questionnaire, to provide reference data for future domestic research.

Our study also had several limitations. First, the participants were mostly from the southern areas of China. Second, the collection of the data for our study was based on self-report, which may lead to confirmation bias of chemosensory disorders. Additional objective assessment of chemosensory disorders is needed in future studies. Third, our study was cross-sectional, and longitudinal studies are needed to determine the direction of associations among variables in our study.

In conclusion, the current study found that the prevalence rates of smell, taste, and chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Patients experienced a general decline in the function of smell, taste, and chemesthesis. Sex, age, smoking, and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may be associated with chemosensory disorders during COVID-19. The present study contributes to existing knowledge of chemosensory disorders in COVID-19 by providing Chinese data collected during Omicron variant dominance.

AUTHORSHIP CONTRIBUTION

Conceptualization, Laiquan Zou; formal analysis, Ying Chen, Yuying Chen, and Laiquan Zou; investigation, Ying Chen, Yuying Chen, Xiang Liu, Chao Yan, and Laiquan Zou; writing−original draft, Ying Chen, Yuying Chen, and Laiquan Zou; writing—review & editing, Xiang Liu, Chao Yan, and Laiquan Zou. All authors have read and agreed to the published version of the manuscript.

FUNDING

None.